On the upside
Antares Pharma (Nasdaq: ATRS) reported upbeat clinical trial results for its Actual Human Use study for VIBEX Methotrexate to treat rheumatoid arthritis.
DARA BioSciences (Nasdaq: DARA) signed agreements that provide the company with comprehensive commercial coverage across the national oncology market.
On the downside
Tesla Motors (Nasdaq: TSLA) blamed slower than expected production of its Model S sedan for cutting its revenue outlook for 2012.
Lexmark International (NYSE: LXK) will replace RadioShack (NYSE: RSH) on the S&P MidCap 400.
Gevo (Nasdaq: GEVO) will halt production of isobutanol from corn and will begin production of ethanol.
In the broad market, declining issues outpaced advancers by a margin of nearly 5 to 4 on the NYSE and on Nasdaq. The Russell 2000 which tracks small cap stocks lost 2 points to 848.